[1] 李胜利, 张婴元, 吴菊芳, 等. 葡萄球菌医院感染的调查研究[J]. 中华医院感染学杂志, 1998, 8(2):65-67. [2] 李梓萌, 孙志, 李威, 等. 金黄色葡萄球菌的耐药性分析及流行病学分型[J]. 中华医院感染学杂志, 2012, 22(12):2485-2487. [3] 周勇, 杨乐和, 林雪峰, 等. 金黄色葡萄球菌临床分离株的耐药谱变迁[J]. 中华医院感染学杂志, 2012, 22(11):2409-2411. [4] Edelsberg J, Weycker D, Barron R, et al. Prevalence of antibiotic resistance in US hospitals[J]. Diagn Microbiol Infect Dis, 2014, 78(3):255-262. [5] Hudson LO, Murphy CR, Spratt BG, et al. Diversity of methicillin-resistant Staphylococcus aureus(MRSA)strains isolated from inpatients of 30 hospitals in Orange County, California[J]. PLoS One, 2013, 8(4):e62117. [6] Köck R, Becker K, Cookson B, et al. Methicillin-resistant Staphylococcus aureus(MRSA):burden of disease and control challenges in Europe[J]. Eurosurveillance, 2010, 15(41):19688. [7] 中华医学会甲氧西林耐药金黄色葡萄球菌感染治疗策略专家组. 中华医学会感染与抗微生物治疗策略高峰论坛:甲氧西林耐药金黄色葡萄球菌感染的治疗策略—专家共识[J]. 中国感染与化疗杂志, 2011, 11(6):401-416. [8] 郑燕红, 蔡海明. 临床感染病原菌分布及耐药菌分析[J]. 医药导报, 2011, 30(9):1222-1223. [9] 赵先颖, 徐元宏, 江晓平. 医院感染葡萄球菌菌种变迁与耐药性近况[J]. 中国微生态学杂志, 2003, 15(1):40-46. [10] 余慧菊, 康金凤, 刘瑛. 合理应用抗菌药物能减缓细菌耐药性产生[J]. 中国科技信息, 2005(12):136-141. [11] Grundmann H, Aires-de-Sousa M, Boyce J, et al. Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat[J]. Lancet, 2006, 368:874-885. [12] Khare M, Keady D. Antimicrobial therapy of methicillin resistant Staphylococcus aureus infection[J]. Expert Opin Pharmacother, 2003, 4(2):165-177. [13] Howden BP, Davies JK, Johnson PDR, et al. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains:resistance mechanisms, laboratory detection, and clinical implications[J]. Clinical Microbiology Reviews, 2010, 23(1):99-139. [14] 刘亚丽, 徐英春. 异质性万古霉素中介金黄色葡萄球菌:困扰我们的难题[J]. 中国感染与化疗杂质, 2013, 13(6):495-498. [15] Park PW, Senior RM, Griffin GL, et al. Binding and degradation of elastin by the staphylolytic enzyme lysostaphin[J]. Int J Biochem Cell Biol, 1995, 27(2):139-146. [16] Ehlert K, Tschierske M, Mori C, et al. Site-specific serine incorporation by Lif and Epr into positions 3 and 5 of the staphylococcal peptidoglycan interpeptide bridge[J]. Journal of Bacteriology, 2000, 182(9):2635-2638. [17] Climo MW, Ehlert K, Archer GL. Mechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus[J]. Antimicrob Agents Chemother, 2001, 45(5):1431-1437. [18] Harrison EF, Cropp CB. Comparative in vitro activities of lysostaphin and other antistaphylococcal antibiotics on clinical isolates of Staphylococcus aureus[J]. Appl Environ Microb, 1965, 13(2):212-215. [19] Yang XY, Li CR, Lou RH, et al. In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from hospitals in Beijing, China[J]. J Med Microbiol, 2007, 56(1):71-76. [20] 杨信怡, 游雪甫, 蒋建东. 溶葡球菌酶的抗菌活性研究进展[J]. 中国新药杂志, 2005, 14(9):1113-1117. [21] 杨信怡, 游雪甫, 娄人慧, 等. 重组溶葡球菌酶的体外抗菌活性研究[J]. 中国新药杂志, 2006, 15(24):2107-2111. [22] 陈旭, 王文奎, 孟志民, 等. 重组溶葡萄球菌素对烧伤创面分离的金黄色葡萄球菌的体外抗菌活性评估[J]. 上海交通大学学报:医学版, 2012, 32(11):1411-1414. [23] Shaw LN, Golonka E, Szmyd G, et al. Cytoplasmic control of premature activation of a secreted protease zymogen:deletion of Staphostatin B(SspC)in Staphylococcus aureus 8325-4 yields a profound pleiotropic phenotype[J]. Journal of Bacteriology, 2005, 187(5):1751-1762. [24] Zygmunt WA, Harrison EF, Browder HP. Microbiological activities of lysostaphin and penicillins against bacteriophage 80/81 strains of Staphylococcus aureus[J]. Appl Environ Microb, 1965, 13(3):491-493. [25] 杨信怡, 游学甫, 蒋建东. 溶葡球菌酶研究进展[J]. 中国生化药物杂志, 2005, 26(6):372-374. [26] 莫云杰, 李国栋, 陆海荣, 等. 重组溶葡萄球菌酶成品中主药蛋白质含量的测定[J]. 中国生化药物杂志, 2006, 27(3):163-165. [27] 卢曦, 任志涛, 李聪然. 重组溶葡萄球菌酶体外诱导的金黄色葡萄球菌耐药株生物学特征[J]. 中国感染与化疗杂志, 2015, 15(3):230-235. |